Biostage Stock Price To Earning
Biostage fundamentals help investors to digest information that contributes to Biostage's financial success or failures. It also enables traders to predict the movement of Biostage OTC Stock. The fundamental analysis module provides a way to measure Biostage's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biostage otc stock.
Biostage |
Biostage OTC Stock Price To Earning Analysis
Biostage's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Biostage Price To Earning | (0.16) X |
Most of Biostage's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biostage is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Biostage has a Price To Earning of -0.16 times. This is 100.62% lower than that of the Biotechnology sector and 103.25% lower than that of the Health Care industry. The price to earning for all United States stocks is 100.56% higher than that of the company.
Biostage Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biostage's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Biostage could also be used in its relative valuation, which is a method of valuing Biostage by comparing valuation metrics of similar companies.Biostage is currently under evaluation in price to earning category among its peers.
Biostage Fundamentals
Return On Equity | -4.92 | |||
Return On Asset | -2.11 | |||
Current Valuation | 78.64 M | |||
Shares Outstanding | 11.64 M | |||
Shares Owned By Insiders | 50.95 % | |||
Number Of Shares Shorted | 121.66 K | |||
Price To Earning | (0.16) X | |||
Price To Book | 28.47 X | |||
EBITDA | (8.36 M) | |||
Net Income | (7.98 M) | |||
Cash And Equivalents | 4.64 M | |||
Cash Per Share | 0.40 X | |||
Total Debt | 115 K | |||
Debt To Equity | 0.04 % | |||
Current Ratio | 2.26 X | |||
Book Value Per Share | (0.16) X | |||
Cash Flow From Operations | (2.63 M) | |||
Short Ratio | 3.35 X | |||
Earnings Per Share | (0.89) X | |||
Target Price | 3.0 | |||
Beta | -0.91 | |||
Market Capitalization | 73.82 M | |||
Total Asset | 1.87 M | |||
Retained Earnings | (65.78 M) | |||
Working Capital | 7.23 M | |||
Current Asset | 7.88 M | |||
Current Liabilities | 654 K | |||
Net Asset | 1.87 M |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Biostage OTC Stock
If you are still planning to invest in Biostage check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biostage's history and understand the potential risks before investing.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |